Video

Dr. Chen Discusses Management of Early Stage, Advanced CTCL

Pei-Ling Chen, MD, PhD, says management of cutaneous T-cell lymphoma requires a multidisciplinary team of specialists including dermatologists and radiation oncologists.

Pei-Ling Chen, MD, PhD, is a member of the Pathology and Cutaneous Oncology Departments at Moffitt Cancer Center and a member of the Moffitt Cutaneous Lymphoma Multidisciplinary Clinic specializing in the the research and treatment of patients with transformed cutaneous T-cell lymphoma (CTCL).

CTCL is incurable but treatable and patients with early stage disease have good prognosis. In advanced stages, CTCL is can be disfiguring and lethal, often requiring multiple rounds and recurrent courses of therapy.

Dr Chen says that management of the disease usually requires a multidisciplinary team of specialists in dermatology, hematology/oncology, dermatopathology, and radiation oncology. Patients with early-stage disease typically receive skin-directed therapies, such as topical steroids, UVB and PUVA phototherapy, and local radiation.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP